Christopher Liu
Stock Analyst at Lucid Capital
(3.49)
# 2,300
Out of 5,118 analysts
150
Total ratings
41.3%
Success rate
5.8%
Average return
Main Sectors:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCT Nuvectis Pharma | Reiterated: Buy | $22 → $34 | $20.91 | +62.60% | 3 | Aug 5, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | $14 → $4 | $0.7953 | +402.95% | 2 | Jun 5, 2026 | |
| NXTC NextCure | Reiterated: Buy | $25 | $5.33 | +369.04% | 2 | Jun 2, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $50 | $22.05 | +126.76% | 1 | May 28, 2026 | |
| ACTU Actuate Therapeutics | Reiterated: Buy | $5 | $0.3288 | +1,420.68% | 1 | May 18, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $14 | $3.90 | +258.97% | 1 | Mar 2, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $42 → $6 | $0.9578 | +526.44% | 2 | Feb 4, 2026 | |
| ANL Adlai Nortye Group | Initiated Coverage: Buy | $11 | $10.28 | +7.00% | 1 | Jan 29, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $50 | $15.43 | +224.04% | 1 | Dec 15, 2025 | |
| IPHA Innate Pharma | Initiated Coverage: Buy | $8 | $1.44 | n/a | 1 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $14.86 | n/a | 1 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $2.00 | n/a | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $1.96 | n/a | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $0.9095 | n/a | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $19 → $37 | $69.57 | n/a | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $36 | $15.30 | n/a | 20 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $0.84 | n/a | 1 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $31.24 | n/a | 7 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $31.65 | n/a | 28 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $18.60 | n/a | 4 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.10 | n/a | 14 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $77 | $6.41 | n/a | 22 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $10.57 | n/a | 12 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $11.59 | n/a | 2 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $27 | $3.82 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.293 | n/a | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $36.43 | n/a | 2 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $15.85 | n/a | 2 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.3806 | n/a | 1 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0111 | n/a | 2 | Jul 6, 2018 |
Nuvectis Pharma
Aug 5, 2026
Reiterated: Buy
Price Target: $22 → $34
Current: $20.91
Upside: +62.60%
Cardiff Oncology
Jun 5, 2026
Reiterated: Buy
Price Target: $14 → $4
Current: $0.7953
Upside: +402.95%
NextCure
Jun 2, 2026
Reiterated: Buy
Price Target: $25
Current: $5.33
Upside: +369.04%
Faeth Therapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $22.05
Upside: +126.76%
Actuate Therapeutics
May 18, 2026
Reiterated: Buy
Price Target: $5
Current: $0.3288
Upside: +1,420.68%
Relmada Therapeutics
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $3.90
Upside: +258.97%
Tvardi Therapeutics
Feb 4, 2026
Upgraded: Buy
Price Target: $42 → $6
Current: $0.9578
Upside: +526.44%
Adlai Nortye Group
Jan 29, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $10.28
Upside: +7.00%
Ascentage Pharma Group International
Dec 15, 2025
Initiated Coverage: Buy
Price Target: $50
Current: $15.43
Upside: +224.04%
Innate Pharma
Oct 23, 2025
Initiated Coverage: Buy
Price Target: $8
Current: $1.44
Upside: n/a
Sep 26, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $14.86
Upside: n/a
Sep 18, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $2.00
Upside: n/a
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $1.96
Upside: n/a
May 28, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $0.9095
Upside: n/a
May 14, 2025
Reiterated: Hold
Price Target: $19 → $37
Current: $69.57
Upside: n/a
Apr 9, 2025
Reiterated: Buy
Price Target: $28 → $36
Current: $15.30
Upside: n/a
Jan 27, 2025
Reiterated: Buy
Price Target: $20
Current: $0.84
Upside: n/a
Feb 21, 2024
Reiterated: Buy
Price Target: $50
Current: $31.24
Upside: n/a
Feb 20, 2024
Reiterated: Buy
Price Target: n/a
Current: $31.65
Upside: n/a
Feb 13, 2024
Reiterated: Buy
Price Target: $18
Current: $18.60
Upside: n/a
Dec 13, 2023
Reiterated: Buy
Price Target: $14
Current: $3.10
Upside: n/a
Dec 8, 2023
Reiterated: Buy
Price Target: $70 → $77
Current: $6.41
Upside: n/a
Nov 9, 2023
Reiterated: Hold
Price Target: $5
Current: $10.57
Upside: n/a
Aug 9, 2018
Rated: Buy
Price Target: $13
Current: $11.59
Upside: n/a
Aug 2, 2018
Rated: Buy
Price Target: $27
Current: $3.82
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $0.293
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $36.43
Upside: n/a
Jul 6, 2018
Reiterated: Hold
Price Target: n/a
Current: $15.85
Upside: n/a
Jul 6, 2018
Reiterated: Hold
Price Target: n/a
Current: $0.3806
Upside: n/a
Jul 6, 2018
Reiterated: Hold
Price Target: n/a
Current: $0.0111
Upside: n/a